Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.


GREY:TBPMQ - Post by User

Comment by Golddetectoron Aug 08, 2022 7:29am
105 Views
Post# 34878042

RE:RE:RE:Guy latest video

RE:RE:RE:Guy latest video

Below is what was published on July 14 ma&d. Last q had similar comment. Sounds close I thought it won't take more than weeks last q but here we are still waiting:

"On June 6, 2022, the Company confirmed that it had completed the Annual Licence Review process for its Health Canada Drug Establishment Licence (“DEL”) and meets the regulatory requirements of C.01A.009 of the Food and Drug Regulations to maintain its DEL for the distribution of pharmaceuticals, like REDUVOTM, in Canada. Any company that intends to distribute pharmaceutical drugs in Canada must obtain a DEL as per Health Canada regulatory requirements. On December 30, 2020, the Company submitted its first New Drug Submission (“NDS”) for REDUVOTM to Health Canada to obtain a Drug Identification Number (“DIN”) for the prescription drug. The Company is in discussions with Health Canada to address final commentary on the submission."



Normandt wrote: For sure he is confident. This drug is approved in the USA already and a few other countries. It was even approved here in Canada 10 years ago. Then everybody knows that HC will approve it.....but the question is..."when?".

 

<< Previous
Bullboard Posts
Next >>